Clinical Trial Update: Immunotherapy Study for Surgically Resected Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial update for an immunotherapy approach in surgically resected pancreatic cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Pancreatic Cancer | Phase 3 | Status: COMPLETED